Storz
Executive Summary
American Cyanamid subsidiary receives April 11 reg letter on promotion of Ocuvite, a zinc supplement for eyes. FDA said the company has been promoting the vitamin and mineral product as a prevention or treatment for such conditions as senile macular degeneration, cataracts, night blindness, severe near-sightedness and injuries to the cornea, which constitute drug claims. Storz said that it would meet with FDA at the beginning of the week of May 7 to discuss the agency's objections. In the meantime, the company has stopped all promotion, including journal ads and mailings, for the product, which is manufactured by Lederle. Storz said that Ocuvite promotions target ophthalmologists to encourage them to recommend the product as a preferred zinc supplement to their patients, and that FDA objections probably were directed at a brochure being distributed that specifically mentioned certain eye conditions.
You may also be interested in...
'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: